Condition: Multiple Myeloma in Relapse · Multiple Myeloma, Refractory · Sponsor: Oncotherapeutics
Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.
This description comes directly from the study's public registry record.
Richard Bailey · 310-464-2190 · rbailey@oncotherapeutics.com
Yohana Sebhat · 310-810-3158 · ysebhat@oncotherapeutics.com
Always discuss trial participation with your own doctor first.
| Berenson Cancer Center | West Hollywood, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06225310